Alzheimer's disease (AD) is the most common cause of dementia but the changes in brain cell function underlying memory loss remains poorly understood. Researchers at the University of Bristol have ...
New research has identified the specific biological mechanism behind the muscle dysfunction found in myotonic dystrophy type 1 (DM1) and further shows that calcium channel blockers can reverse these ...
UNIVERSITY PARK, Pa. -- L-type calcium channel blockers (LCCBs) -- the most widely used drugs for treating hypertension -- may harm the heart as much as help it, according to a new study. The research ...
Culture and Sensitivity Nondihydropyridine calcium channel blockers (non-DHP CCBs) appear to reduce proteinuria in patients with diabetic kidney disease Nondihydropyridine calcium channel blockers ...
Active ingredient: Clevidipine butyrate emulsion 0.5 mg/mL; solution for IV infusion; contains lipids 0.2 g/mL (soybean oil, egg phospholipids). Indication: To reduce BP when oral therapy is not ...
Praxis Precision Medicines' ulixacaltamide (PRAX-944) is a potent and selective small molecule T-type Ca2+ channel blocker being developed for the potential treatment of essential tremor. ET is a ...
Calcium channel blocker toxicity represents a significant clinical challenge owing to its multifaceted pathophysiology and potential to precipitate life‐threatening cardiovascular compromise. Overdose ...
A type of blood pressure lowering medication, called a calcium-channel blocker, may be linked with an increased risk of a type of bowel condition called diverticulosis. This condition causes small ...
Alzheimer's disease (AD) is the most common cause of dementia but the changes in brain cell function underlying memory loss remains poorly understood. Researchers at the University of Bristol have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback